CureMeAbroad, an artificial-intelligence discovery platform for medical tourism, has closed a pre-seed round of $600,000, Entrackr reported. It drew a group of angel investors that included Roman Saini, Himanshu Ratnoo, Kunal Gupta, Devaiah Bopanna and Vikrant Potnis. The company was co-founded in June 2025 by Aditya Oza and Mikhail Bohra, and it sets out to connect international patients with hospitals, surgeons and treatment destinations across borders.
Where the pre-seed money goes
CureMeAbroad said the capital would go into three parts of its discovery engine, Entrackr reported. The first is its own AI cost estimator, the second is a set of clinical matching models, and the third is a multilingual patient intelligence layer that reads and answers queries across languages. Each of those pieces addresses a specific friction in cross-border care, and the company frames them as the core of how patients find and compare providers. Cost estimation is the load-bearing one. International patients rarely know the price of a procedure before they travel, and a tool that quotes it in advance removes one of the sharpest anxieties in the medical tourism journey.
The platform’s reported scale
CureMeAbroad describes itself as an AI-first discovery platform, and the figures Entrackr reported set out its early footprint. Its cost estimator has been trained on more than 634 procedure records, which is what lets it return indicative pricing rather than a vague range. The directory lists over 6,000 hospitals across 47 countries and 45 specialities, and the company works with more than 380 accredited partner hospitals in five destinations, Mexico, Turkey, Thailand, India and Georgia. The platform operates under HIPAA certification, the United States standard for handling patient data, which matters for a service moving medical records across jurisdictions.
That country list is not random. Mexico, Turkey, Thailand, India and Georgia are among the biggest medical tourism destinations, each with a price edge over the source markets CureMeAbroad wants to reach, and each already handling large volumes of foreign patients. Building the first partner network where demand and supply already exist is the sensible order of work, and it is cheaper than manufacturing a destination from scratch.
The market the round is betting on
This timing tracks a market that is still expanding. A recent market report, cited by Entrackr, projects global medical tourism to reach $174 billion by 2035, driven by the familiar mix of cheaper treatment, faster access and procedures that patients cannot obtain at home. Patients leave home for one of five reasons, that care abroad is better, is the best available, is cheaper, is faster, or is simply unavailable where they live. A discovery platform is a bet that the search itself is the bottleneck rather than the supply of clinics, and that medical tourism at heart is a symptom of unequal access that better information can partly route around.
The problems CureMeAbroad wants to solve
CureMeAbroad frames its pitch around the failures of the existing market, Entrackr reported. It names a lack of trust, opaque pricing, a reliance on informal WhatsApp agents, unverified clinic listings and limited aftercare accountability as the recurring reasons patients hesitate. The company plans to push into three source markets first, the GCC, the United Kingdom and Africa, each a region that already sends patients abroad in volume and each short of capacity at home.
There is a long-standing critique of this segment that the pitch has to answer. The medical tourism trade carries too many middlemen who sell visibility rather than trust, ranking the clinics that pay rather than the clinics that perform, and a platform built on verified listings and transparent pricing is only ever as good as the verification behind it. A directory of 6,000 hospitals is an asset and a liability at once, because breadth is easy to advertise and quality is hard to guarantee. The 380 accredited partners are the more meaningful figure, and the ratio between that curated network and the wider directory is the number worth tracking.
Aftercare and the limits of a directory
Aftercare is the hardest of the problems on the list. Medical travel carries four distinct risks, clinical, legal redress, continuity of care, and the logistical exposure of treatment in a foreign system, and a discovery platform touches only the first meeting between patient and provider. The complications that surface after a patient flies home, and the question of who owns them, sit outside a matching engine, and limited aftercare accountability is the failure most likely to erode the trust CureMeAbroad says it wants to build. Solving discovery is the easy half, and the platform will be judged on the part that starts once the procedure is done.
A crowded competitive set
CureMeAbroad enters a field with incumbents. Entrackr named Bookimed, PlacidWay, The Medical Tourism Company and Medical Departures as competitors, each an established cross-border booking or discovery platform with years of listings already behind it. The AI framing is the differentiator CureMeAbroad is leaning on, and whether an estimator trained on 634 records and a multilingual layer prove enough to displace incumbents is the open question a $600,000 round cannot yet answer.
What to watch
A pre-seed round funds a thesis, not a track record. The tests are specific. Whether the 380-strong accredited network grows faster than the raw directory will show whether the company is buying quality or breadth. Whether the cost estimator’s quotes hold up against the invoices patients actually receive will show whether the transparency claim survives contact with the market. And whether the GCC, the United Kingdom and Africa convert into booked procedures, rather than registered users, will show whether the discovery layer solves a real bottleneck. The funding is a signal of investor confidence, Entrackr reported, and the procedures, not the round, will settle the rest.
